孙丰润;李默晗;贺渝淼;王涛;马超;黄宇光;
SUN Fengrun;LI Mohan;HE Yumiao;WANG Tao;MA Chao;HUANG Yuguang;Department of Human Anatomy,Histology and Embryology,Institute of Basic Medical Sciences,Chinese Academy of Medical Sciences,School of Basic Medicine,Peking Union Medical College;Department of Anesthesiology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College;Joint Laboratory of Anesthesia and Pain,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Un

• 1:中国医学科学院基础医学研究所北京协和医学院基础学院人体解剖与组织胚胎学系
• 2:中国医学科学院北京协和医院麻醉科
• 3:中国医学科学院北京协和医院麻醉-疼痛联合实验室

摘要(Abstract)：

目的 对复合多聚体材料组成的局麻药缓释载体的药物释放特征和镇痛效果进行测评。方法 使用静电纺丝技术制备含盐酸布比卡因的PLGA(聚乳酸-羟基乙酸共聚物)缓释膜(静电纺丝膜，M组),并以PLGA-PEG(聚乙二醇)-PLGA温敏凝胶包裹纺丝膜制备成含盐酸布比卡因的缓释递送系统(凝胶包裹静电纺丝膜形成的复合缓释载体，G组),评定两组体外释放特征、体内镇痛效果及安全性。结果 体外条件下，M组对盐酸布比卡因的累积释放时间可达5 d以上，G组累积释放时间可延长至10 d。体内条件下，M组和G组对坐骨神经慢性压迫损伤大鼠模型的镇痛时间均可达14 d,两组镇痛效果无显著差异(P>0.05)。M组盐酸布比卡因血药浓度在术后第1天达峰值[(0.294±0.029)μg/L],G组于术后第3天达峰值[(0.192±0.064)μg/L],且峰值较M组降低，两组盐酸布比卡因血药浓度均在安全范围内。HE染色示，M组、G组大鼠的心脏、肝脏、脾脏、肺、肾脏组织均未见明显病理改变。结论 本研究制备的以盐酸布比卡因纳米纺丝缓释膜为基础，PLGA-PEG-PLGA温敏凝胶包裹为介质的复合缓释材料，可进一步延长盐酸布比卡因缓释时间，具有长效镇痛效果且无毒性作用。
Objective To evaluate the release characteristics and analgesic effect of extended-release composite polymers of local anesthetics.Methods Polymer extended-release film containing bupivacaine hydrochloride was prepared via electrospinning(nanomembrane, group M), and was furthermore loaded intoPLGA-PEG-PLGA thermo-sensitive gel forming composite extended-release carrier(group G). The in vitro release profile, analgesic effect and safety in vivo were evaluated. Results In vitro, the cumulative release of bupivacaine hydrochloride reached more than 5 d in the group M and 10 d in the group G. In vivo, the analgesic effect in the model of chronic compression injury of sciatic nerve lasted for 14 d in the group M and group G. There was no significant difference between the two groups(P>0.05). The peak plasma concentration of bupivacaine hydrochloride in the group M was(0.294±0.029)μg/L one day after drug administration, while(0.192±0.064)μg/L in the group G three days after drug administration, which were far below the toxic plasma level of bupivacaine chloride. Meanwhile, there were no significant pathological changes in the heart, liver, spleen, lung and kidney of the two groups. Conclusions In this study, the composite extended-release drug delivery prepared by bupivacaine hydrochloride electrospinning film as the basis and PLGA-PEG-PLGA thermo-sensitive gel can further prolong the release time of bupivacaine chloride and exhibit long-term analgesic effect without toxicity.

关键词(KeyWords)： 缓释局麻药;静电纺丝;温敏凝胶;聚合物药物递送载体;盐酸布比卡因
extended-release local anesthetics;electrospun film;thermo-sensitive gel;polymeric drug carrier;bupivacaine chloride

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金面上项目(81771205);; 中国博士后科学基金面上项目(2020M680453)~~

作者(Authors): 孙丰润;李默晗;贺渝淼;王涛;马超;黄宇光;
SUN Fengrun;LI Mohan;HE Yumiao;WANG Tao;MA Chao;HUANG Yuguang;Department of Human Anatomy,Histology and Embryology,Institute of Basic Medical Sciences,Chinese Academy of Medical Sciences,School of Basic Medicine,Peking Union Medical College;Department of Anesthesiology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College;Joint Laboratory of Anesthesia and Pain,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Un

参考文献(References)：

• [1] Hernandez-Boussard T,Graham LA,Desai K,et al.The Fifth Vital Sign:Postoperative Pain Predicts 30-day Readmissions and Subsequent Emergency Department Visits[J].Ann Surg,2017,266:516- 524.
• [2] Cohen SP,Vase L,Hooten WM.Chronic pain:an update on burden,best practices,and new advances[J].Lancet,2021,39:2082- 2097.
• [3] Mitra S,Carlyle D,Kodumudi G,et al.New Advances in Acute Postoperative Pain Management[J].Curr Pain Headache Rep,2018,22:35.
• [4] Ward EN,Quaye AN,Wilens TE.Opioid Use Disorders:Perioperative Management of a Special Population[J].Anesth Analg,2018,127:539- 547.
• [5] Kalkman GA,Kramers C,Van Dongen RT,et al.Trends in use and misuse of opioids in the Netherlands:a retrospec-tive,multi- source database study[J].Lancet Public Health,2019,4:e498- e505.
• [6] Fallon M.When morphine does not work[J].Support Care Cancer,2008,16:771- 775.
• [7] He Y,Qin L,Huang Y,et al.Advances of Nano-Structured Extended-Release Local Anesthetics[J].Nanoscale Res Lett,2020,15:13.
• [8] Sekimoto K,Tobe M,Saito S.Local anesthetic toxicity:acute and chronic management[J].Acute Med Surg,2017,4:152- 160.
• [9] He YM,Qin LN,Fang YH,et al.Electrospun PLGA nanomembrane:A novel formulation of extended-release bupivacaine delivery reducing postoperative pain[J].Mater Des,2020,193:108768.
• [10] Alejo T,Uson L,Landa G,et al.Nanogels with High Loading of Anesthetic Nanocrystals for Extended Duration of Sciatic Nerve Block[J].ACS Appl Mater Interfaces,2021,13:17220- 17235.
• [11] Kaye AD,Armstead-Williams C,Hyatali F,et al.Exparel for Postoperative Pain Management:a Comprehensive Review[J].Curr Pain Headache Rep,2020,24:73.
• [12] Balocco AL,Van Zundert PGE,Gan SS,et al.Extended release bupivacaine formulations for postoperative analgesia[J].Curr Opin Anaesthesiol,2018,31:636- 642.
• [13] Kharitonov V.A review of the compatibility of liposome bupivacaine with other drug products and commonly used implant materials[J].Postgrad Med,2014,12:129- 138.
• [14] El-Say KM,El-Sawy HS.Polymeric nanoparticles:Promis-ing platform for drug delivery[J].Int J Pharm,2017,528:675- 691.
• [15] Zhang W,Ning C,Xu W,et al.Precision-guided long-acting analgesia by Gel-immobilized bupivacaine-loaded microsphere[J].Theranostics,2018,8:3331- 3347.
• [16] Padmakumar S,Joseph J,Neppalli MH,et al.Electrospun Polymeric Core-sheath Yarns as Drug Eluting Surgical Sutures[J].ACS Appl Mater Interfaces,2016,8:6925- 6934.
• [17] Weldon CB,Tsui JH,Shankarappa SA,et al.Electrospun drug-eluting sutures for local anesthesia[J].J Control Release,2012,161:903- 939.
• [18] Sadeghi-Avalshahr A,Nokhasteh S,Molavi AM,et al.Synthesis and characterization of collagen/PLGA biodegradable skin scaffold fibers[J].Regen Biomater,2017,4:309- 314.
• [19] Wang T,Hurwitz O,Shimada SG,et al.Anti-nociceptive effects of bupivacaine-encapsulated PLGA nanoparticles applied to the compressed dorsal root ganglion in mice[J].Neurosci Lett,2018,668:154- 158.
• [20] Bennett GJ,Xie YK.A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man[J].Pain,1988,33:87- 107.
• [21] Wu C,Xu J,Kang S.Animal Models of Postoperative Pain[J].Anim Models Pain,2011,49:181- 200.
• [22] Gaudette F,Benito J,Steagall P,et al.Assessment of tandem mass spectrometry and high-resolution mass spectro-metry for the analysis of bupivacaine in plasma[J].Biomed Chromatogr,2015,29:1724- 1730.
• [23] Finnerup NB,Kuner R,Jensen TS.Neuropathic Pain:From Mechanisms to Treatment[J].Physiol Rev,2021,101:259- 301.
• [24] Mir M,Ahmed N,Rehman AU.Recent applications of PLGA based nanostructures in drug delivery[J].Colloids Surf B Biointerfaces,2017,159:217- 231.
• [25] Zorzetto L,Brambilla P,Marcello E,et al.From micro-to nanostructured implantable device for local anesthetic delivery[J].Int J Nanomedicine,2016,11:2695- 2709.
• [26] Mcalvin JB,Reznor G,Shankarappa SA,et al.Local toxicity from local anesthetic polymeric microparticles[J].Anesth Analg,2013,116:794- 803.
• [27] Schmidt B,Ohri R,Wang JC,et al.Local pathology and systemic serum bupivacaine after subcutaneous delivery of slow-releasing bupivacaine microspheres[J].Anesth Analg,2015,120:36- 44.